Compare FSI & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FSI | INKT |
|---|---|---|
| Founded | 1991 | 2017 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.2M | 70.6M |
| IPO Year | 2000 | 2021 |
| Metric | FSI | INKT |
|---|---|---|
| Price | $6.30 | $11.93 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $35.00 |
| AVG Volume (30 Days) | 21.1K | ★ 37.3K |
| Earning Date | 04-15-2026 | 05-15-2026 |
| Dividend Yield | ★ 1.53% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $15,494,325.00 | N/A |
| Revenue This Year | $63.39 | N/A |
| Revenue Next Year | $43.77 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.22 | $6.80 |
| 52 Week High | $11.48 | $76.00 |
| Indicator | FSI | INKT |
|---|---|---|
| Relative Strength Index (RSI) | 49.80 | 54.93 |
| Support Level | $5.89 | $10.79 |
| Resistance Level | $6.67 | $12.55 |
| Average True Range (ATR) | 0.22 | 1.01 |
| MACD | -0.02 | 0.19 |
| Stochastic Oscillator | 52.08 | 67.05 |
Flexible Solutions International Inc develops, manufactures, and markets specialty chemicals that slow the evaporation of water. Its business is organized into two segments: Energy and Water Conservation Products and Biodegradable Polymers. It offers a liquid swimming pool blanket under the WATERSAVR brand, which saves energy and water by inhibiting evaporation from the pool surface, and a chemical product called HEATSAV for use in swimming pools and spas to slow water evaporation. The company also manufactures and markets water-soluble chemicals utilizing thermal polyaspartate biopolymers. It generates the majority of its revenues from the export of its products to international markets.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.